The use of pharmacologic agents in the treatment of pulmonary hypertension has not proved to be uniformly successful or predictable. One possible reason for the vagaries in response is that the pulmonary vascular lesions are not consistent. We examined the relation between the structure of the pulmonary resistance vessels in unexplained (primary) pulmonary hypertension and the response to pulmonary vasodilators. Our study involved 19 patients with clinically unexplained pulmonary hypertension (mean pressure, 59±14 mm Hg). After characterizing them clinically and performing control hemodynamic measurements, we determined the acute effects of a series of vasodilator agents that have different mechanisms of action. In 16 patients, lung biopsy material was related to the hemodynamic studies; in nine patients, including six who had undergone open lung biopsy, the hemodynamic studies were related to the pathologic changes found at autopsy. Histologic specimens from all 19 patients were evaluated qualitatively and sorted into three subsets of hypertensive pulmonary arteriopathy: medial hypertrophy (with minimal intimal proliferation), arteriopathy with plexiform lesions (associated predominantly with concentric laminar intimal proliferation and fibrosis), and arteriopathy with microthrombotic lesions (associated predominantly with eccentric intimal proliferation and fibrosis). The 16 lung biopsies were also quantitated by morphometric techniques. Using a decrease in calculated pulmonary vascular resistance of more than 30% accompanied by a decrease in mean pulmonary arterial pressure of at least 10% to define vasodilation, only four patients were responders. The patients varied considerably in their responses to different vasodilator agents. Patients with similar clinical and hemodynamic profiles differed considerably with respect to the nature of their pulmonary vascular obstructive lesions and their responses to vasodilator agents. Qualitative histologic examination of lung tissue did not provide a basis for predicting how individual patients would respond to vasodilator agents. However, quantitative morphologic analysis of the initial open lung biopsy specimens did prove helpful in predicting acute responsiveness to vasodilator agents and the subsequent clinical course of these patients with unexplained (primary) pulmonary hypertension. An intimal area of more than 18% of the vascular cross-sectional area had an 85% predictive value for identifying the patients who did poorly during the first 36 months of follow-up. (Circulation 1989;80:1207-1221 U xnexplained," or "primary," pulmonary hypertension (PPH) is a clinical syndrome in which the common denominator is pul-
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Methods

Patient Population
Nineteen of the patients referred to the Hospital of the University of Pennsylvania between January 1980 and December 1984 for the evaluation of unexplained pulmonary hypertension comprised the population for this study. The clinical characteristics of each patient are given in Table 2 . This and all subsequent tables are organized according to the histologic classification outlined in Table 1 and detailed below. In no patient did more than 1 month elapse between lung biopsy and the initial trial of vasodilator agents. All patients were determined to have precapillary pulmonary vascular lesions. Seven additional patients who underwent open lung biopsy for unexplained pulmonary hypertension were excluded from this series. These patients were determined to have postcapillary pulmonary vascular lesions (three patients) or identifiable etiologies for their pulmonary hypertension (e.g., sarcoidosis, scleroderma, pulmonary fibrosis, talc granulomatosis). Follow-up data are reported through December 1987.
In six patients (2, 11, 13, 14, 16, and 18) , two sets of histologic data were obtained: by lung biopsy at the time of initial evaluation and at autopsy after they died of right ventricular failure. For one of these (patient 13), two sets of hemodynamic data were obtained: an initial trial of vasodilators while the patient was not in heart failure and a second vasodilator study 3 days before death when the patient was in a state of severe unremitting right heart failure.
Hemodynamic Studies
For right heart catheterization and evaluation of the responsivity of the pulmonary circulation to the acute administration of vasodilators, all 19 patients were admitted to the Clinical Research Center or Medical Intensive Care Unit of the Hospital of the University of Pennsylvania. Written consent for the procedures was obtained in each instance. Vasodilators had previously been discontinued. All other medications were withheld on the morning of catheterization. A flotation, triple-lumen, thermodilution catheter was advanced into the pulmonary artery to record right atrial, PA, and occlusion Palevsky et al Primary Pulmonary Hypertension 1209 manner was rounded to the nearest 5. In those who did not have clinical tricuspid insufficiency, the CO (1/min) was determined in the supine position by the thermodilution method. All thermodilution measurements were done at least in triplicate to ensure reproducibility; the mean of three values, which differed from one another by less than 15%, appear in Table 2 . In those patients who had clinical evidence of tricuspid regurgitation, the CO was determined by Fick principle. Systemic arterial pressure was determined intermittently by standard sphygmomanometry or by an automated blood pressure cuff (Dinamap 845 xT, Critikon, Tampa, Florida). Heart rate was determined from a continuous electrocardiographic recording. Blood pressures in the pulmonary circulation and the electrocardiogram were continuously recorded at the bedside; all pressures shown in Table 2 were measured at end expiration.
Vasodilator Studies
After introducing the PA catheter, systemic and PA pressures were recorded and CO repeatedly was measured for at least 30 minutes until reproducible baseline values were obtained. The vasodilator agents and dosages used are detailed in Table 3 . On the average, six agents were tested in each patient (mean, 5.6; range, two to eight). Serial determinations of PA pressure, PA0 pressure, and CO were made during and after the administration of each agent to trace the course of the hemodynamic response, to determine the maximal effect, and to ensure return of the hemodynamic measurements to baseline values before administering the next agent in the series. The administration of any of the vasodilator agents was discontinued if the arterial blood pressure decreased to less than 95 mm Hg, if the heart rate exceeded 120 beats/min, or if the PA systolic pressure increased by more than 10 mm Hg over the baseline value.
The sequence in which the agents were given was varied at random except that hydralazine was usually given last because of its prolonged duration of action. In each instance, baseline PA hemodynamics were allowed to return to control values before the next vasodilator agent was given. The time required to reestablish baseline differed from agent to agent and from patient to patient. In patients [3] [4] [5] Based on values given as mean+±2 SD as the expected range of variability, we adopted a decrease in mean PA pressure that exceeded 10% as a significant decrease in PA pressure. Our major reason for adopting these criteria is that a decrease in PA pressure in conjunction with a decrease in PVR would be expected to be of long-term benefit in decreasing the work of the right ventricle.
Pathology
Seventeen of the 19 patients underwent thoracotomy for diagnostic lung biopsy; one specimen was a thin strip of peripheral lung tissue containing few blood vessels and was considered unsatisfactory for these analyses. Lung tissue was sampled randomly from either the left or right lung while the lungs were kept inflated; the lingula and the tip of the right middle lobe were not used for biopsy because histologic changes in these regions may not be representative of the lungs as a whole.17 ' 
Pathologic Classification
Based on the predominant histopathologic lesions found in the preacinar and intra-acinar muscular arteries, the patients were classified into three groups (Table 1) (Figure 1 , Panel A). The media was abnormally thick and the elastic laminae in the small muscular arteries were reduplicated, often in association with distal extension and thickening of arteriolar smooth muscle.
In group 2 (arteriopathy with plexiform lesions), the predominant vascular lesion was a concentric, onion skin-like proliferation of myofibroblasts and elastic fibers in the intima of the small muscular arteries and arterioles accompanied by abundant acellular connective tissue ( Figure 
Morphometric Studies
Morphometric analysis was performed on VvGstained sections projected from a Zeiss microscope (at x160 magnification) onto a digitizing graphics tablet connected to an Apple lIe computer (Apple Computer, Cupertino, California). Transversely sectioned precapillary vessels of 50-500 ,um in external diameter were analyzed by tracing the external elastic lamina (i.e., outer circumference of the vessel and of the media), the internal elastic lamina (i.e., outer circumference of the intima, inner circumference of the media), and the luminal circumference (i.e., inner circumference of the intima) with a stylus connected to the microcomputer (Figure 1 , Panel E). The area occupied by the media (AM), the intima (A), and the residual lumen were then calculated as a percentage of the total vessel cross-sectional area (Av). Vessel wall area (Aw=AI+AM) was also determined (Figure 1 , Panels E and F).
Ratios of areas were used rather than wall thickness to normalize for the 10-fold variability in the size of the vessels examined. The degree of contraction of the vessels did not influence the measurements because ratios of surface area measurements rather than absolute values were measured and because the length of the contracted internal and external elastic laminae was traced with the stylus and normalized by the computer to that of smooth circular profiles. This method has the advan- 
Statistical Methods
Comparisons of the clinical, hemodynamic, and vasodilator characteristics of the three histologic groups were made by analysis of variance. Correlation between the hemodynamic data and the severity (i.e., grade) of pulmonary vascular disease was tested by the Kendall-Spearman rank-correlation test. Significance was determined atp less than 0.05 level for all comparisons.
Relations between morphometric parameters and hemodynamic data were examined by plotting the morphometric parameter on the abscissa (independent variable) and the hemodynamic measurement on the ordinate (dependent variable). Data were analyzed by visual inspection, with a least-squares linear regression formula, and by multiple curvefitting formulas to evaluate relations. 33 Multivariate regression models were constructed with baseline hemodynamic measurements and morphometric parameters as independent variables for the prediction of changes in mean PA pressure and PVR.34
Results
Clinical and Hemodynamic Profile
The clinical characteristics of the study population are tabulated in Table 2 . The clinical and laboratory features, including chest radiographs and ventilation-perfusion lung scans, did not distinguish between histologic groups. The mean age of the patients was 36.5+13.9 years. Although there was a trend toward age differences between the histologic groups (group 1 averaged 38.2±+11.7 years, group 2 averaged 25.3±5.5 years, and group 3 averaged 42.6+14.7 years), the differences were not statistically significant. Nor could duration of symptoms be related to histologic group.
The hemodynamic data for the 19 patients are also presented in (3) are traced by computer stylus to determine the crosssectional area of the media and the intima and the total cross-sectional area of the vessel. To normalize these data, the results were expressed as ratios: for the media, the area between the external and internal elastic laminae divided by the total area within the external elastic lamina multiplied by 100 (AM/Avx100); for the intima, the area between the internal elastic lamina and the luminal circumference divided by the total area within the exter- used as an estimate of left ventricular filling pressure, was normal at rest in all patients, averaging 7.3 ±3.5 mm Hg.
The mean PA pressure for group 2 (mean, 71.3±10.9 mm Hg) was higher than for group 1 (mean, 56.0±12.0 mm Hg) and significantly higher than for group 3 (mean, 51.9±11.1 mm Hg) (p<0.005). The resting cardiac index (CI) averaged 2.26±0.75 1/min/m2 for the entire group. Group 2 had a mean CI (1.86±0.61 1/min/m2) that was significantly less than that of group 3 (mean CI, 2.57±0.67 1/min/m2) (p<0.05). Group 1 had a mean CI of 2.05±1.03 1/min/m2.
The mean PVR for all patients was 1,246±508 dyne-sec cm-5 (range, 540-2,490 dyne-sec-cm-5). Group 2 had a significantly higher mean PVR (1,658±456 dyne-sec cm-5) than group 3 (mean PVR, 1,022±622 dyne-sec cm-5 [p<0.01]). Group 1 had a mean PVR of 1,168±545 dyne-seccm-5.
In patient 13, two sets of hemodynamic observations were made in the course of the disease: the first when she was not in heart failure and was clinically stable albeit exercise-intolerant (13a in Vasodilator Responses Each of the 19 patients received a battery of vasodilator agents either intravenously or sublingually (nifedipine). The responses to the six agents given to a majority of the patients are presented in Table 4 . In seven of the 19 patients, at least one vasodilator agent elicited a decrease in calculated PVR of more than 30%. However, in only four was this decrease in PVR accompanied by a 10% decrease in mean PA pressure. In one patient, the PVR decreased by more than 30% with essentially no change in mean PA pressure (-5%) (patient 2); in the other two patients, the decrease in PVR was associated with a large increase in CI and an increase in mean PA pressure (patients 10 and 16).
The number of agents that elicited vasodilation in a particular patient ranged from one to three. In all patients, the hemodynamic responses to the different vasodilator agents varied considerably (Table 4) .
It should be emphasized that some patients responded to one agent but not to another and that the agents that elicited a defined response differed from patient to patient. In addition, all but one of the patients who did manifest vasodilation after at least one agent also exhibited no vasodilation or an adverse response to at least one other agent.
Pathologic Classification
Pulmonary tissue, obtained by open lung biopsy, at autopsy, or both, was available in all 19 patients ( Table 5 ). Sixteen of the 19 patients had satisfactory open lung biopsy specimens available; autopsy material alone was available in three patients. Both biopsy and autopsy material were available in six others.
The patients were subdivided into three groups on histologic grounds1819'21'31 (see "Methods").
Group 1 contained three patients; group 2 contained six patients; and group 3 contained 10 patients. The correlation between biopsy and autopsy was excellent; all six patients had both specimens classified into the same histologic groups.
Morphometrtic Studies
The morphometric analyses of the histology specimens from the 16 lung biopsy specimens are detailed in Table 6 . Three components of the vessel were assessed separately; the lumen, the intimal layer, and the media. In all patients, the PA lumens were decreased, and the intima and media were increased in area.
Lumen. In all patients, the lumens of the resistance vessels were decreased in caliber because the vessel walls were inordinately thick (i.e., the ratio of vessel wall area to the total cross-sectional area of the vessel [ Changes over time. The mean cross-sectional area of the vessel wall did not change over time in the three patients who had both biopsy and autopsy specimens studied with morphometric analyses (57.0% vs. 57.5%). However, the area of the intima increased significantly (mean increase, 16.6%), whereas the area of the media decreased reciprocally. In patient 13, who underwent vasodilator studies at both these times, the morphometric changes were associated with a loss of vasodilator responsiveness.
Comparison of Hemodynamics and Vasodilator Responses
No correlation could be demonstrated between vasodilator response and any baseline hemodynamic variable.
Comparisons of Pathology and Vasodilator Responses
No statistically significant correlation could be demonstrated between histologic pattern and pharmacoreactivity.
The patterns of response observed did not correlate statistically with either the extent of medial hypertrophy or the presence or absence of medial fibrosis. Despite this lack of statistical correlation, vasodilator responses occurred in one of nine patients with medial fibrosis and in three of 10 patients without medial fibrosis.
Comparisons of Morphometry With Hemodynamics and Vasodilator Responses
Baseline. Of the three morphometric parameters measured on the initial open lung biopsy specimens, In this respect, our experience differs from that of Rich et al,25 whose patients seemed to be more prone to spontaneous swings in PA blood pressure. Nor have such swings been reported by others except in a rare patient with pulmonary hypertension.2,24,43 In our series, the spontaneous variations in baseline mean PA pressure averaged 5.7+1.8%. We used this mean+2 SD value as one element in judging whether a vasodilator response occurred after drug administration.
Defining Vasodilation
The conventional criterion for deciding that a test agent has elicited pulmonary vasodilation is a decrease in calculated PVR of more than 20-30%.23,24,43 Had we elected to use a 20% decrement in PVR as the criterion,12 then 15 of our 19 patients would have been considered to be responders. With 30% as the criterion, seven of our patients exhibited a vasodilator response to at least one test agent. However, to take into account the work of the heart, we added a concomitant decrease in mean PA pressure as a second criterion. Using the criteria of a 30% decrease in PVR and a 10% decrease in PA pressure, only four patients manifested pulmonary vasodilation that was apt to be of long-term therapeutic benefit.
Vasodilator Responses
There is currently no ideal pulmonary vasodilating agent available for either acute or chronic administration by oral route.12 In our study, maximal vasodilation was elicited by eight different agents. A pharmacologic agent that proved effective as a pulmonary vasodilator in one patient would fail to exert a pulmonary vasodilator effect in another, often despite similar pulmonary vascular lesions. Moreover, in the individual patient who did respond to more than one vasodilator, the magnitude of the vasodilation differed from one agent to another (Table  4) . This variability necessitated the testing of multiple vasodilator agents that exert their vasodilator effects by different pharmacologic mechanisms to determine the optimal drug for each patient. Although we did not increase all agents to maximum-tolerated dosage and, therefore, some of the observed variability could reflect differences in dosage rather than in effectiveness, it is clear that the patients did respond preferentially to different agents. Recent results with prostacyclin or acetylcholine have raised the possibility that these agents afford the prospect of sorting patients with pulmonary hypertension into responders and nonresponders.44-47 Nonetheless, trials with several agents are still necessary to determine the "best" agent for a particular patient.
Correlations Between Baseline Hemodynamics and Vasodilator Responses
The acute responses to vasodilators did not correlate with either the pretest values for the CO, PVR, or mean PA pressure. Reeves et a124 had found that sustained (more than 3 months) clinical benefit from vasodilator therapy correlated with the magnitude of the decrease in PVR in response to acute vasodilator testing; in addition, the more marked vasodilator responses occurred in those with the lower initial PVR values. However, although two of our patients with "positive" vasodilator responses had PVR of less than 850 dyne-sec cm-5 (patients 3 and 12), patient 8 Even though the plexiform lesion has been listed as a hallmark of one of the histologic groupings (group 2), its significance remains unknown. However, the patients with plexiform lesions were younger, had higher PVRs, higher PA pressures, and lower CIs than did the patients in the other two groups. This raises the possibility that the plexiform lesion is either a marker of the rapidity of the development of pulmonary vascular injury or a consequence of severe pulmonary hypertension and not indicative of a specific etiology or pathogenetic mechanism. This view is supported by recent studies of familial PPH that disclosed marked heterogeneity of pulmonary vascular lesions despite presumably related etiology and pathogenesis. 48 Microthrombotic lesions have proved to be quite common in patients with PPH. The etiology and significance of these microthrombotic lesions is unknown. We suspect that they represent in situ thrombosis rather than embolic events. 31 Patients with PPH are quite distinct clinically from those with pulmonary hypertension due to recurrent or unresolved pulmonary emboli49 and neither we, nor other centers,50 have been able to find sources of emboli in PPH. One possibility to account for in situ thrombosis is endothelial injury secondary to high intravascular pressure. This would explain why microthrombotic lesions occur in patients with pulmonary hypertension of diverse etiologies and would account for reports of benefit from anticoagulation in patients with pulmonary hypertension.51 Parenthetically, chronic infusions of prostacyclin seem to benefit even those patients with PPH who manifest no vasodilator response during acute administration of the agent,52 possibly due to the potent antiplatelet effects of prostacyclin. This prospect raises the question of whether all patients with pulmonary hypertension should be treated with antiplatelet agents.
Open Lung Biopsy
We resorted to lung biopsy in these patients with unexplained pulmonary hypertension for three reasons: 1) the possibility of uncovering etiologies and pathogenetic mechanisms (i.e., "secondary" pulmonary hypertension), 2) the substantial side effects of the pharmacologic pulmonary vasodilators, and 3) the hope of finding structural-functional correlates in the pulmonary circulation that could serve as a guide for choice of agents. 20, 31 One concern about the value of lung biopsy is the extent to which it represents the overall disease process. Previous studies in patients with pulmonary vascular disease have suggested that histologically the concordance between biopsy and autopsy is close. 30, 53 We found this to be confirmed in our patients. However, the focal lesions (e.g., plexiform lesions) were more common at autopsy because of the greater number of vessels available for examination. Therefore, even though open lung biopsy does provide an adequate representation of the extent, nature, and degree of pulmonary vascular pathology, the frequency of individual vascular lesions may be greater at autopsy.
We had anticipated that the qualitative histologic features at biopsy would provide a basis for identifying the individual who would respond to pulmonary vasodilators. It seemed reasonable to expect that the degree of medial hypertrophy would reflect the potential for vasomotor responsiveness, whereas intimal fibrosis might limit the capability to vasodilate. This proved not to be the case. The only generalization that we could reach is that the more severe the intimal lesions and the medial fibrosis the less apt is the hypertensive pulmonary circulation to respond to vasodilator agents.
Lung biopsy was generally well tolerated. Four patients died during the hospitalization in which they underwent open lung biopsy; one of an esophageal variceal bleed, two of unremitting right heart failure; and one of an apparent perioperative myocardial infarction; only in the latter case was the biopsy procedure believed to have been related to the patient's death. Nonetheless, because lung biopsy did not change the therapeutic approach in most patients with PPH, we do not recommend routine lung biopsy in these patients. We reserve lung biopsy for those patients in whom some feature of the presentation, laboratory workup, or clinical course raises the suspicion that the disorder is not an instance of "typical" PPH.
Morphometry in Primary Pulmonary Hypertension
The normal PA bed is composed of thin-walled vessels with an intima that is only one cell layer thick and a media that varies with vessel size but ranges between 1.3% and 7% vessel thickness (maximum, 13.5% of vessel cross-sectional area) in normal vessels less than 2,000 ,um external diameter. 54 Experimental models of pulmonary hypertension (i.e., monocrotaline, hypoxia, high-flow states, thromboembolism) have suggested a pattern of sequential changes in vascular morphology, most prominent in the arterial vessels less than 500 ,um in diameter.55-59A progression of increased muscularization, followed by intimal hyperplasia that may progress to luminal occlusion has been described. 60 Whether a concomitant reduction in the density of the arterial vascular bed occurs as part of the initiating pathologic process or secondary to sustained pulmonary hypertension is still being debated.21,22,61 With respect to reversibility, it is the consensus that hypertrophy and cellular hyperplasia are capable of regressing, whereas fibrosis and vascular occlusion are not.
Similar conclusions have been reached relating lung biopsy to the course of pulmonary hypertension after repair of congenital cardiac defects12 '20-22: Medial hypertrophy and cellular intimal proliferation have often proved reversible, whereas concentric intimal fibrosis has only regressed when it was mild.21 More pronounced intimal fibrosis barely regressed, or even progressed, after repair of the underlying cardiac pathology.
Previous evaluations of the severity of pulmonary vascular changes in PPH have been descriptive with classification such as that introduced by Heath and Edwards62 and subsequently modified by Wagenvoort.63 Although these classifications have been useful in standardizing descriptions of pulmonary vascular disease, they are based on the assumption that the evolution of vascular lesions in PPH is similar to that in pulmonary hypertension associated with congenital heart disease. Moreover, these classifications are based on the most severe vascular changes (e.g., plexiform lesions, arteritis) and ignore the variability of the lesions with respect to severity and the occurrence of thrombotic intimal lesions. 63 Quantification of the pulmonary vascular lesions as in this study supplements the histologic observations cited above. For example, the area of the vascular media in the resistance vessels correlated significantly with the level of PAd pressure, particularly when it increased to more than 30 mm Hg. This suggests that sustained elevation of the PAd may be the stimulus for the medial hypertrophy seen in PPH. CO also had value as an independent predictor of vascular media; combined with PAd it improved the correlation with AM/Av.
The inverse relation between the area of the media and area of the intima is consistent with previous work showing that continued elevation of PA pressures, in particular, the PAd pressure, which initially causes medial hypertrophy, is eventually succeeded by intimal hyperplasia and atrophy of the media.29 Morphometric data (Table 6 ) from the three patients with both biopsy and autopsy suggests that this progression is accomplished with little change in the cross-sectional area of the vessel wall: the lumen is relatively unaffected despite histologic progression.
Morphometry and Vasodilator Trials
Our findings relating the histopathologic changes with vasodilation (i.e., acute reversibility) after pharmacologic intervention are in accord with previous reports.21 '22 The percent change in both mean PA pressure and PVR correlated best with the percent of the vessel wall occupied by the media. The more marked the intimal thickening, the less the vasodilator responsiveness and the more rapid the clinical deterioration.
Predicting Vasodilator Responsiveness
The relations described by the multivariate regression equations between the morphometric parameters and the postvasodilator changes observed in hemodynamic parameters may make it possible to predict which patients have a reasonable prospect of responding to pharmacologic intervention. If lung biopsy is to be performed, morphometry appears to add to the information gained by routine histologic evaluation. Once the intima has increased to represent a substantial proportion of the vessel crosssectional area, regardless of the status of other structures, the vessel will not significantly dilate (i.e., it has become functionally fixed). Vasodilator trials do not appear warranted in such patients. 65 Predicting Clinical Course Our data do not support the previously published suggestion that a decrement of 20% or more in PVR during acute vasodilator trials can be used to predict clinical outcome.23 Excluding the patient lost to follow-up at 2 months, eight of 14 studies in the group that worsened rapidly and six of seven studies in the group that remained stable over 36 months had at least one response of this magnitude. Only the difference in intimal areas was significant in our analysis and could predict clinical course.
The two complete data sets from patient 13 and the two sets of morphometric data from patients 2 and 11 strengthen the observations presented above. responses to the vasodilator agents could not be related to their place in the testing sequence.
